BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29757439)

  • 21. Is ITP a thrombophilic disorder?
    Rodeghiero F
    Am J Hematol; 2016 Jan; 91(1):39-45. PubMed ID: 26547507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment.
    Moulis G; Bagheri H; Sailler L; Jonville-Bera AP; Weber E; Guy C; Petitpain N; Laroche ML; Favrelière S; Béné J; Baldin B; Villeval-Federici L; Tebacher-Alt M; Bres V; Veyrac G; Grandvuillemin A; Mauprivez C; Lapeyre-Mestre M; Montastruc JL;
    Eur J Intern Med; 2014 Oct; 25(8):777-80. PubMed ID: 25242516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
    Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
    [No Abstract]   [Full Text] [Related]  

  • 25. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eltrombopag-Induced Thrombocytosis and Thrombosis in Patients With Antiphospholipid Syndrome and Immune Thrombocytopenic Purpura.
    Oo Z; Manvar K; Wang JC
    J Investig Med High Impact Case Rep; 2022; 10():23247096211060581. PubMed ID: 35277086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
    Kuter DJ
    Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
    Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
    Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New thrombopoietin receptor agonists for platelet disorders.
    Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
    Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.
    Catalá-López F; Corrales I; de la Fuente-Honrubia C; González-Bermejo D; Martín-Serrano G; Montero D; Saint-Gerons DM
    Med Clin (Barc); 2015 Dec; 145(12):511-9. PubMed ID: 26051432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis.
    Tjepkema M; Amini S; Schipperus M
    Crit Rev Oncol Hematol; 2022 Mar; 171():103581. PubMed ID: 35007700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
    Qu MM; Liu XN; Liu XG; Feng Q; Liu Y; Zhang X; Liu S; Zhang L; Li GS; Zhu YY; Lv MY; Peng J; Hou M
    Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
    Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
    [No Abstract]   [Full Text] [Related]  

  • 39. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.